introduct the present case applic revoc patent pursuant patent act cth act 
the patent claim enantiom racem racem disclos claim earlier patent 
thi issu relat compound recent two judgment publish close evid one case close address decis lindgren J alphapharm pti ltd v H lundbeck fca decis full court ranbaxi australia pti ltd v Co llc fcafc respect 
australian patent patent suit appli februari 
the patente 
applic made intern version patent suit februari novemb 
It contend prioriti date later second date 
the term patent suit extend pursuant provis Pt Ch act five year 
thu patent suit due expir februari 
each apotex pti ltd apotex spirit pharmaceut pti ltd spirit seek revoc patent suit ground lack novelti lack invent step manner manufactur inutil fals suggest misrepresent 
both proceed heard togeth bodi evid one set reason given 
chemic background the titl invent specif enantiom methyl thieno pyridyl process prepar pharmaceut composit contain 
the compound subject claim patent suit intern name clopidogrel 
after obtain regulatori approv product launch name plavix activ ingredi bisulf salt clopidogrel 
It success commerci 
It inhibit platelet aggreg site blood vessel damag inhibit thrombu clot format 
It admit applic apotex intend make sell composit activ ingredi clopidogrel bisulf would breach claim patent suit 
the invent relat organ chemistri concern studi carbon compound particular stereochemistri carbon compound respect three dimension structur molecul 
isom compound whose molecul consist number kind atom differ structur arrang 
materi rotat plane polaris light said optic activ 
the mean identifi compound properti shine plane polaris light sampl compound dissolv appropri solvent measur extent rotat 
If compound display optic activ indic chemic structur molecul mirror imag 
that properti call chiral molecul describ chiral 
An organ compound said chiral centr includ carbon atom bond four differ substitu 
If structur molecul mirror imag mirror imag must differ molecul 
In case optic activ pure compound two two isom call enantiom differ structur arrang atom space mirror imag 
enantiom ident physic chemic properti except two import respect rotat plane polaris light opposit direct though equal amount interact differ way chiral compound includ react differ rate 
the isom rotat plane polaris light left counter clockwis call levo isom enantiom design one rotat plane polaris light right clockwis call dextro isom D enantiom design 
although pure compound alway optic activ compos chiral molecul mixtur equal amount enantiom optic inact sinc equal opposit rotat cancel 
A mixtur compris equal amount two enantiom often design prefix 
such mixtur call racem mixtur racem 
the separ racem mixtur two optic activ enantiom call resolut 
the racem chemic formula enantiom 
there debat common gener knowledg resolv enantiom racem mixtur australia prioriti date patent suit 
I shall return issu 
In broad term salt chemic compound form combin acid base acid compound characteris abil donat proton surround wherea basic compound characteris abil accept proton surround 
salt may form crystallin compound 
issu critic relat pharmaceut drug includ efficaci toler toxic 
these refer pharmacolog properti compound ie oper compound vivo 
thi invent appli biolog system compos chiral molecul 
becaus enantiom interact chiral molecul differ way often behav differ biolog system 
thi result differ physiolog effect 
An enantiom may also undergo racem convert mixtur enantiom vivo 
patent suit the bodi specif commenc follow the compound invent correspond follow formula I asymmetr carbon atom 
In fact formula repres molecul claim well enantiom 
the racem mixtur correspond formula pcr describ french patent applic publish No 
hereaft enantiom claim accord invent design Id enantiom Il 
It known optic rotatori power compound depend solvent measur concentr solvent 
the optic rotatori power isom accord invent posit methanol solut 
In unexpect manner enantiom Id exhibit platelet aggreg inhibit activ enantiom Il inact 
moreov inact enantiom Il less well toler two enantiom 
the invent also relat addit salt compound formula Id pharmaceut accept miner organ acid 
the specif outlin detail product certain salt compound method separ enantiom convert salt determin enantiom puriti 
discuss pharmacolog studi follow introduc thu the platelet aggreg inhibit activ toxic new compound compar racem mixtur describ french patent No 
public No 
pcr 
A descript given result studi demonstr anoth advantag invent name salt isom better therapeut index salt racem mixtur fact isom exhibit almost platelet aggreg inhibit activ toxic markedli higher homologu 
emphasi ad 
the conclus includ follow the result obtain aggreg adp hydrochlorid racem mixtur pcr hydrogen sulfat SR C SR C isom one hand pcr hydrochlorid SR A SR A shown tabl demonstr isom inact isom least activ racem 
for aggreg collagen percentag inhibit differ slope curv repres variat optic densiti function time control product test divid slope control multipli 
the result shown tabl II demonstr isom activ wherea salt compar activ 
the result present tabl iii show isom inact test contrast isom racem 
the number dead anim determin day administr compound studi 
the lethal dose thu determin express weight salt administ present tabl IV result show one hand toxic racem mixtur similar isom wherea isom markedli less toxic hand toxic depend natur acid use form salt 
the pharmacolog studi present demonstr interest inhibitori properti toward platelet aggreg compound Id absenc activ isom Il 
On account interest inhibitori properti toward platelet aggreg interfer mechan format arteri venou thrombos medicin invent use administ treatment prevent platelet disord due extracorpor blood circuit consequ complic atheroma 
the signific claim case 
isom methyl thieno pyridyl pharmaceut accept salt 
hydrogen sulfat isom methyl thieno pyridyl 
process prepar compound accord claim compris format salt racem methyl thieno pyridyl optic activ acid solvent repeat recrystal salt carri product constant optic rotatori power obtain isom liber salt base necessari salt format carri pharmaceut accept acid 
french patent develop clopidogrel the french patent applic refer specif suit file juli 
it titl new deriv thieno pyridin process prepar therapeut applic 
the specif commenc follow thi invent relat new thieno pyridin process prepar therapeut applic 
the new deriv invent follow gener formula Y repres OH group OR group R straight branch lower alkyl radic Y repres group independ hydrogen straight branch lower alkyl group RI form togeth nitrogen attach heterocycl may includ second heteroatom oxygen nitrogen wherein latter may substitut lower alkyl benzyl radic may substitut X repres hydrogen halogen lower alkyl radic 
these compound asymmetr carbon may exist form two enantiom 
the invent relat enantiom mixtur 
emphasi ad 
exampl number said given amongst other illustr invent follow methyl 
chlorophenylacet X deriv No 
A method prepar compound set 
after give exampl specif went the result pharmacolog toxicolog test report demonstr properti deriv invent term toxic toler activ level deriv especi inhibit action aggreg activ 
thu invent also relat therapeut composit particular inhibit action aggreg action wherein activ ingredi deriv formula I addit salt thereof pharmaceut accept miner organ acid Y repres group OR miner base Y OH 
variou investig report includ relat deriv said the toxicolog pharmacolog investig report demonstr low toxic compound invent well excel toler inhibit properti aggreg activ make use medic therapeut applic 
claim follow compound formula Y repres OH group OR group R straight branch lower alkyl radic Y repres group RI independ hydrogen straight branch lower alkyl group form togeth nitrogen atom attach heterocycl may includ second heteroatom oxygen nitrogen wherein latter may substitut lower alkyl benzyl radic may substitut X repres hydrogen halogen lower alkyl radic addit salt pharmaceut accept organ acid Y repres OR group miner base Y repres OH well two enantiom mixtur 
methyl 
deriv ndeg 
therapeut composit aggreg inhibit activ activ contain activ ingredi deriv formula I claim claim addit salt thereof pharmaceut accept miner organ acid miner base well one two enantiom mixtur 
emphasi ad 
exampl deriv subject claim correspond formula patent suit 
the racem mixtur known intern pcr 
patent correspond french patent also grant canada canadian patent No canadian patent australia australian patent No patent unit state US patent No US patent 
these four patent reli upon prior art patent case 
A brief chronolog develop clopidogrel follow In commenc research thienopyridin 
grant variou patent around world includ australian patent prioriti date februari compound includ ticlopidin 
ticlopidin launch franc australia 
subsequ launch becam awar report rare potenti fatal side effect patient 
after discoveri ticlopidin continu research potenti valuabl thienopyridin hope find compound better platelet aggreg inhibit properti 
In synthesis thienopyridin compound identifi pcr 
unlik ticlopidin pcr racem compound 
test racem compound pcr indic activ platelet aggreg inhibitor ticlopidin caus trembl convuls even death test anim 
In march Mr badorc employe direct Dr maffrand succeed separ enantiom pcr 
the enantiom name pcr enantiom name pcr 
the result anim test enantiom pcr indic pcr activ pcr inact pcr toxic test human 
In earli work pcr abandon 
In synthesis anoth racem thienopyridin compound identifi pcr 
It similar structur pcr 
test racem compound pcr demonstr platelet inhibit activ toler better pcr favour ticlopidin 
A decis made separ enantiom pcr 
Mr badorc undertook exercis 
Mr badorc attempt separ enantiom diastereomer salt format techniqu fail 
He ultim obtain enantiom mean asymmetr synthesi process 
the enantiom name pcr pcr respect 
test enantiom indic activ enantiom similar racem indic advantag racem 
from commenc synthesis compound complic function group pcr pcr 
A seri compound synthesis test ultim juli synthesis racem compound pcr 
test result indic pcr better toler effect ticlopidin 
In total compound formula synthesis refer exampl canadian patent australian patent well prior art patent 
the test result compound report prior art patent indic toxic problem effect 
In determin develop pcr 
the prior art patent obtain case australian patent prioriti date juli 
pcr compound identifi exampl prior art patent 
pcr underw develop test 
between report side effect anim particular convuls 
between acut long term toxic test pcr undertaken rat mice baboon 
phase I studi human volunt carri precursor obtain regulatori approv permit sale pcr therapeut compound 
In novemb Dr maffrand decid attempt obtain enantiom pcr 
thi decis made light advers side effect test result pcr report time 
between novemb februari Mr badorc unsuccess attempt obtain separ enantiom pcr mean asymmetr synthesi 
Mr badorc attempt diastereomer salt format 
there debat precis order event march Mr badorc carri experi ad 
g 
mole acid solut g 
mole pcr solut ml aceton 
crystal appear within hour 
the concentr pcr solvent experi significantli higher earlier experi 
subsequ analysi demonstr experi produc enantiom pcr 
On april Mr badorc obtain enantiom pcr make acid use chiral resolv agent 
the method obtain enantiom pcr later name clopidogrel specifi patent suit method employ march describ except patent specifi use acid 
the preliminari test clopidogrel perform use form hydrochlorid salt obtain Mr badorc 
thi salt suitabl test unstabl difficult formul 
In particular hygroscop 
subsequ hydrobromid hydrogen sulfat taurochlor salt enantiom pcr made 
the enantiom test 
A review test result indic Dr maffrand enantiom pcr activ enantiom activ 
the initi pharmacolog test indic enantiom less well toler enantiom 
the enantiom name clopidogrel 
subsequ acut toxicolog test indic inact enantiom twice toxic activ enantiom caus convuls test anim activ enantiom 
applic made intern version patent suit februari convent applic patent suit made februari intern file date prioriti 
In mid late toxicolog test undertaken respect pcr enantiom clopidogrel 
thi test provid confirm pcr enantiom caus convuls clopidogrel 
In april decid abandon develop work pcr 
phase I human test clopidogrel commenc decemb 
after obtain regulatori approv launch name plavix 
common gener knowledg the common gener knowledg relev case encompass broad term known relat follow aspect organ chemistri hypothet skill invent worker field australia the fundament principl stereochemistri method obtain individu enantiom racem the format salt stereochem compound pharmaceut purpos the activ toxic stereochem compound abil predict 
sever expert wit gave evid relev assess state common gener knowledg 
evid behalf applic given Dr keith geoffrey watson professor martin gerhardt banwel professor bevyn jarrott professor ian david rae 
evid behalf respond given relevantli professor christoph john easton professor peter john scammel 
professor shaun phillip jackson also gave evid respond Dr maffrand Mr badorc 
the evid wit contribut appreci common gener knowledg australia relev case 
those portion evid professor jackson ultim admit went specif question concern natur platelet aggreg patholog manifest oper clopidogrel platelet aggreg inhibitor 
professor jackson obtain bachelor medic scienc degre monash univers 
set first broad outlin evid given expert wit relat four issu includ broad outlin studi profession activ expert 
there follow summari state common gener knowledg distil consider evid 
befor commenc analysi note relat issu fundament stereochemistri outlin hear two tutori one prepar Dr watson applic professor easton latter includ comment applic tutori 
despit area disagr identifi comment fundament principl stereochemistri relevantli disput parti 
A broad outlin principl inform parti tutori includ 
the comment relat issu thu direct instead certain key principl question wide principl recognis australia 
Dr watson Dr watson obtain bachelor scienc honour chemistri monash univers 
He obtain phd chemistri monash univers 
between Dr watson occupi postdoctor posit chemistri imperi colleg london csiro victoria 
hi postdoctor work involv chemic synthesi deriv natur product molecul test biolog system 
between Dr watson work research offic later senior research offic senior princip research scientist ici australia central research laboratori victoria 
Dr watson work ici focus develop commercialis select herbicid drug treat heart diseas 
these appoint involv applic synthet organ chemistri prepar small molecul biolog activ 
Dr watson experi princip area herbicid 
sinc Dr watson attend confer australia oversea relev field interest 
Dr watson also regularli read book journal relev field stereochemistri career 
In Dr watson approxim year age 
Dr watson taught fundament stereochemistri undergradu studi henc underli concept well known Dr watson 
prior Dr watson good work knowledg principl stereochemistri relev also issu techniqu resolv racem 
there signific chang scienc stereochemistri sinc 
prior Dr watson awar sever techniqu obtain singl enantiom racem 
diastereomer salt format includ kind undertaken Mr badorc relat pcr today well known routin techniqu obtain enantiom 
that techniqu describ chemic literatur well 
Dr watson could perform techniqu diastereomer salt format prior done though one occas 
ii Dr watson would use diastereomer salt format first techniqu obtain enantiom simplest approach would expect yield suffici analyt test 
Dr watson indic work relat herbicid synthesi relev activ enantiom prefer method given larg commerci quantiti requir 
Dr watson distanc howev suggest asymmetr synthesi separ techniqu view diastereomer salt format would difficult impract industri scale 
Dr watson compar two method say limit method asymmetr synthesi avail prior stage diastereomer salt format tri true method 
A risk racemis order seen relat pcr would dissuad Dr watson use diastereomer salt format relat compound 
all said respond highlight certain comment made Dr watson appear cast doubt enthusiasm relat process diastereomer salt format 
iii prior determin chiral solvent use part diastereomer salt format process Dr watson would begun consult literatur use previous resolv similar compound 
had use inform avail Dr watson would consult list standard readili avail chiral run parallel experi 
parallel experiment common salt format procedur prior 
the use acid resolut new rather well known describ chemic literatur time literatur Dr watson person librari 
further aceton well known wide use readili avail solvent resolut prior choic use part diastereomer salt format process new 
iv Dr watson consid resolut gener rel fast process one would abl determin fairli quickli whether reaction succeed 
As timefram requir obtain yield Dr watson depos various hour day rather month year would requir obtain small quantiti enantiom usual take sever week industri quantiti perhap requir sever month 
the latter refer sever week said respond cast doubt former estim hour day 
the latter estim sought explain apotex respons estim Mr badorc time requir whole process rather time reaction may take hour day 
Dr watson state crystal develop within day particular experi would tri anoth experi parallel differ chiral solvent 
Dr watson consid one would expect succeed persever process 
hydrochlor sulfur acid like lead format good hydrochlor hydrogen sulfat salt crystal respect common acid found chemistri laboratori use routin 
their salt commonli made 
approxim increas activ racem enantiom would expect 
that suffici signific compel separ test singl enantiom racem 
one would expect one enantiom activ littl activ exampl compound display properti found literatur prior 
Dr watson would obtain test singl enantiom rather investig compound class compound 
ii Dr watson consid absent literatur inform particular compound imposs predict toxic enantiom test 
A physiolog activ compound would necessarili toxic physiolog activ necessarili relat toxic 
iii Dr watson consid pharmacolog test enantiom accur method determin characterist theoret approach base molecular model 
Dr watson consid howev properti salt racem use guid properti enantiom 
professor banwel professor banwel obtain bachelor scienc honour the victoria univers wellington 
He obtain phd organ chemistri the victoria univers wellington 
between professor banwel held academ appoint organ chemistri univers australia oversea includ ohio state univers univers adelaid univers auckland univers melbourn 
these appoint involv lectur student research supervis professor banwel research synthesi novel organ molecul includ biolog activ molecul 
dure period professor banwel also involv asymmetr synthesi includ supervis phd student area 
prior professor banwel would consult scientif literatur attend confer meet review patent literatur order remain familiar develop relev field 
In professor banwel approxim year age 
professor banwel taught fundament principl stereochemistri undergradu student possess time copi lead stereochemistri text use teach undergradu student 
there signific chang scienc stereochemistri sinc 
professor banwel consid onward period teach undergradu postgradu chemistri student well awar mani avail method separ racem 
professor banwel supervis upper level undergradu honour student undertak separ multipl occas 
professor banwel capabl prior appli knowledg resolut techniqu laboratori set 
ii prior professor banwel would employ diastereomer salt format techniqu separ enantiom racem mixtur display relev function ident activ enantiom know 
the process diastereomer salt format rel straightforward method describ lead chemistri textbook prior 
He understood time diastereomer salt format effici process 
professor banwel also queri whether asymmetr synthesi techniqu separ enantiom 
iii when resolv chiral base professor banwel would select chiral acid consult literatur relat acid previous use resolv similar compound 
professor banwel familiar acid prior consid classic acid 
He expect enantiomer form would commerci avail 
professor banwel would known prepar chiral form acid 
professor banwel would consult literatur relat choic solvent undertak diastereomer salt format select would hing compound resolv professor banwel commonli use ethanol methanol aceton water 
professor banwel would run variou experi parallel straightforward approach experi prior would taken less hour set 
iv result diastereomer salt format would expect within minut day 
had professor banwel sought obtain enantiom react diastereomer salt strong miner base undertak repeat crystallis desir enantiomer puriti reach techniqu also well develop prior would yield outcom day week 
If attempt formul pharmaceut accept salt amin form oil professor banwel would consult literatur commonli use acid salt format similar compound 
prior salt describ claim patent suit well known professor banwel acid requir produc readili avail 
By professor banwel well understood enantiom often exhibit differ biolog activ includ therapeut activ toxic 
professor banwel cite exampl thalidomid repres potenti differ activ enantiom taught undergradu student onward thalidomid exampl 
It becam clear professor banwel thalidomid exampl fact support gener proposit one enantiom pair may activ may complet inact 
the thalidomid exampl fact demonstr simpli enantiom pair may exhibit substanti differ activ case thalidomid one enantiom found possess bulk therapeut sed effect possess neg teratogen effect 
By professor banwel understood direct relationship exist desir biolog activ pair enantiom toxic 
It would surpris professor banwel time desir activ present one enantiom toxic 
professor jarrott professor jarrott obtain bachelor pharmaci first class honour univers queensland 
He obtain phd pharmacolog univers cambridg focus research vivo disposit chemic amin adrenalin 
after doctor studi professor jarrott work four year lectur pharmacolog monash univers 
In professor jarrott commenc period work honorari clinic pharmacologist austin hospit victoria 
between professor jarrott work senior lectur appoint reader clinic pharmacolog therapeut unit depart medicin austin hospit 
from professor jarrott involv research univers melbourn concern mechan action drug block bind transmitt receptor arteri heart muscl brain 
from part research team work develop 
professor jarrott research cardiovascular hypertens requir regular analysi test biolog properti chiral compound includ pharmacolog properti individu enantiom 
professor jarrott state involv drug develop work would begin chemist isol compound compound interest biolog activ relat therapeut target preliminari vitro test activ toxic conduct 
professor jarrott involv select activ compound investig thereaft produc suffici efficaci data enabl registr compound therapeut good administr 
In professor jarrott approxim year age 
professor jarrott taught fundament stereochemistri undergradu pharmacolog student 
professor jarrott acquir prior copi textbook wide use undergradu pharmacolog lectur mani discuss basic principl stereochemistri 
there major advanc chang principl known prior separ techniqu 
prior professor jarrott familiar techniqu use obtain enantiom learn undergradu student 
professor jarrott awar techniqu diastereomer salt format 
It known well develop fairli routin separ method prior often taught undergradu scienc student 
prior professor jarrott familiar techniqu use formul scientist formul salt learn honour student 
prior today formul pharmaceut accept salt involv select appropri reagent acid base 
professor jarrott well understood sinc undergradu student enantiom exhibit differ biolog activ therapeut activ toxic 
prior professor jarrott would expect differ pharmacolog activ enantiom relat relev receptor 
professor jarrott understood prior similar activ pair enantiom quit unusu commonli one enantiom activ 
accord professor jarrott differ activ would quit commonli approxim differ would expect howev one point professor jarrott state would expect least differ activ enantiom 
It would unexpect two enantiom compound display activ 
equal professor jarrott understand prior less activ enantiom gener exhibit activ rare complet inact 
ii professor jarrott depos level toxic enantiom difficult predict separ test toxic like pharmacolog activ enantiom inact enantiom 
prior professor jarrott would expect toxic level differ enantiom 
professor rae professor rae obtain diploma appli chemistri footscray technic school 
He obtain bachelor scienc univers melbourn master scienc univers melbourn 
hi undergradu master studi involv consider stereochemistri 
professor rae obtain phd australian nation univers 
between professor rae undertook postdoctor work north america nation research council ottawa univers toronto massachusett institut technolog boston 
hi work univers toronto work period involv stereochemistri though stereochemistri remain key area interest professor rae throughout 
He regularli attend seminar present confer read literatur concern part least stereochemistri 
between professor rae work chemistri monash univers various univers research fellow senior lectur associ professor 
professor rae teach work period requir teach fundament stereochemistri undergradu student 
In professor rae approxim year age 
professor rae awar principl stereochemistri prior 
the concept racem may differ enantiomer form inform taught univers student 
between professor rae caus consult lead textbook relat stereochemistri 
there major advanc stereochemistri principl diastereomer salt format techniqu sinc though method obtain enantiom develop wide use 
professor rae knew resolut diastereomer salt format prior consid standard 
other techniqu also known prior 
professor rae recal evid colleagu taught cours includ discuss theori resolv racem diastereomer salt format 
asymmetr synthesi also well develop method prior professor rae consid separ process 
ii professor rae would elect use diastereomer salt format rather asymmetr synthesi obtain enantiom racem 
resolut techniqu well known proven prior 
professor rae depos necessari conduct extens experiment undertak diastereomer salt format well known establish protocol process chemist could work appli routin manner 
parallel experi would usual use 
when undertak develop activ drug racem professor rae would elect obtain enantiom rather undertak studi relev class compound 
professor rae would agre method use obtain particular enantiom involv routin experiment 
iii professor rae would use diastereomer salt format mean obtain enantiom consult literatur choos resolv acid like regard opt cheapest acid readili avail 
choic resolv acid base could readili assist relev literatur own professor rae prior 
when use diastereomer salt format professor rae would expect yield suffici allow activ analysi enantiom obtain 
professor rae various depos yield could expect known within day would gener take week obtain particular enantiom resolut month year 
prior format salt activ enantiom oil achiev quit straightforward routin techniqu prior 
prior behaviour racem regard salt format would like use guid behaviour enantiom 
professor rae would consid sulfur acid phosphor acid highli relev attempt obtain salt 
professor rae state characterist enantiom obtain could predict 
nevertheless prior professor rae awar would expect enantiom particular racem compound would differ biolog properti almost alway one activ littl none 
prior professor rae would expect racem less activ activ enantiom activ enantiom would gener twice activ racem 
prior today biolog activ enantiom could determin separ test 
ii professor rae consid imposs generalis relationship toxic versu desir activ 
It would unexpect find activ enantiom toxic inact enantiom toxic 
professor easton professor easton obtain bachelor scienc doubl major chemistri flinder univers 
He obtain bachelor scienc honour physic organ chemistri flinder univers 
He obtain phd organ chemistri univers adelaid 
professor easton undertook work postdoctor fellow chemistri harvard univers work area organ chemistri bacteri resist penicillin 
In professor easton work research fellow institut advanc studi research school chemistri australian nation univers involv project deal organ biolog chemistri relat penicillin biosynthesi 
between professor easton first lectur later senior lectur chemistri univers canterburi new zealand continu work penicillin biosynthesi involv synthesi compound studi interact biolog target molecul 
from professor easton lectur organ chemistri univers adelaid 
In professor easton approxim year age 
professor easton outlin affidavit evid tutori basic principl stereochemistri known relat relev date differ relev manner appear understood expert wit prior 
enantiom would obtain trial error possibl predict whether particular method would work 
professor easton would sought obtain enantiom racem chanc one enantiom may display increas activ rather would investig relat group compound 
ii professor easton cite variou textbook cast doubt upon simplic diastereomer salt format method obtain enantiom 
the choic salt relat enantiom patent suit would matter trial error 
It possibl predict effect toxic particular enantiom without obtain test 
knowledg structur relev receptor enantiom would direct may provid guidanc enantiom complementari chiral receptor like activ pair 
professor scammel professor scammel obtain bachelor scienc chemistri includ organ chemistri life scienc griffith univers 
He obtain bachelor scienc degre honour focus synthet medicin chemistri griffith univers 
from professor scammel undertook research toward phd synthet medicin chemistri griffith univers 
In professor scammel approxim year age 
the stereochemistri describ prior art patent chemistri professor scammel person familiar rel straightforward chemistri similar professor scammel would expect undergradu honour student abl perform practic work final year research project public date prior art patent around 
At public date prior art patent professor scammel undergradu student learn broad method resolut asymmetr synthesi variou subset method obtain singl enantiom though perform practic experi 
professor scammel state method known prior possibl predict whether would lead obtain particular enantiom 
ii At public date prior art patent professor scammel would necessarili attempt obtain individu enantiom racem effort increas activ rather would opt wider studi relev class compound 
iii the choic chiral solvent diastereomer salt format matter trial error price eas obtain acid relev factor 
acid one acid among mani might suitabl 
likewis aceton common solvent rang common solvent well certain solvent mixtur 
iv there spectrum difficulti obtain singl enantiom racem 
An attempt obtain enantiom pcr would matter trial error abil predict success use particular method 
the process diastereomer salt format would fix like durat could encompass success process last week complet lack success 
professor scammel appear direct comment relevantli issu 
At public date prior art patent known one enantiom pair may therapeut activ possibl predict activ without test except knowledg structur intend receptor knowledg scarc 
even knowledg intend receptor present case would necessarili enabl predict made 
ii professor scammel state one enantiom therapeut activ greatest increas activ achiev separ racem would 
A greater increas would fairli surpris could possibl one enantiom block activ 
It may also enantiom display therapeut activ activ differ natur enantiom 
iii prior known one enantiom may toxic though may necessarili case 
It possibl predict toxic includ basi therapeut activ 
summari the differ wit state common gener knowledg great extent aris differ qualif experi 
I satisfi synthesi evid give sound idea state relev knowledg australia 
At time relev knowledg princip academ littl evid local pharmaceut drug develop 
I satisfi wit repres fair knowledg avail time 
I also satisfi common featur evid reason basic level albeit complex field 
On basi forego follow emerg indic state common gener knowledg relev field australia relat four issu the principl stereochemistri well known prior 
they well inform concern techniqu obtain enantiom taught undergradu student univers student gener 
there signific chang scienc stereochemistri sinc though certain advanc made understand applic certain techniqu obtain enantiom asymmetr synthesi exampl 
A rang techniqu obtain enantiom racem well known prior 
inform concern techniqu particular diastereomer salt format taught undergradu student though may alway involv practic experiment 
asymmetr synthesi also known techniqu though queri whether understood separ techniqu 
ii prior diastereomer salt format well develop method straightforward routin though involv choic 
those choic includ choic chiral resolv agent acid base requir solvent 
the varieti choic regard well certain factor meant process may well involv trial error experiment carri guarante success 
that howev take process beyond routin experiment includ respect parallel experiment 
though choic certainli exist drug develop process whether obtain enantiom diastereomer salt format say asymmetr synthesi instead inde simpli undertak wider studi relev class compound diastereomer salt format certainli promin wide use well develop techniqu prior 
It clear mani would elect use techniqu first step though obviou disagr point 
though without certain difficulti process known report yield result though necessarili relat thienopyridin compound 
iii As resolv acid base solvent clearli choic made regard 
guidanc could gain literatur though princip would appear similar compound alreadi resolv 
list standard chiral acid amin also avail 
acid known chiral resolv agent prior use new 
it commerci avail enantiomer form perhap certain though possibl prepar chiral form acid 
aceton well known commonli use solvent prior 
further variabl temperatur experi conduct seal shape reaction vessel concentr racem reagent solvent respect amount solvent present room temperatur variabl dealt part normal experiment process 
As apotex allud submiss detail variabl appear warrant particular focu patent suit 
iv the time might expect elaps obtain yield diastereomer salt format process matter differ opinion 
what appear emerg fix like durat process inde abil predict certainti whether one success 
the process may involv immedi success like mean day may drawn week 
month year would expect 
the process may also without success 
the process involv trial error may requir persever 
yield may obtain suffici analysi activ enantiom 
the format pharmaceut accept salt racem enantiom includ form oil common process prior techniqu known 
there choic made relat salt would made process involv trial error henc choic term acid 
hydrochlor sulfur acid howev common laboratori acid use make pharmaceut salt prior 
It well understood prior enantiom exhibit differ biolog activ toxic 
the thalidomid exampl clearli provid cautionari tale regard 
It possibl without separ test predict certainti activ toxic enantiom 
some predict might made base knowledg intend receptor properti salt relev racem knowledg avail still could ensur certainti 
ii there rang potenti differ activ enantiom 
At extrem activ may one enantiom might activ none 
those two extrem howev less like would less expect result intermedi rang 
It unusu one enantiom display activ littl 
the differ activ racem activ enantiom could expect though differ might increas inact enantiom serv inhibit activ activ enantiom present racem 
iii the toxic enantiom relat physiolog activ 
anoth issu state knowledg australia concern possibl variou regulatori author oversea would compel test enantiom racem mix propos registr pharmaceut drug 
I satisfi possibl gener recognis time field 
the unit state food drug administr fda draft guidelin issu earli recommend cours 
there littl doubt would widespread knowledg guidelin australia 
there evid similar view europ japan 
revoc befor turn examin ground revoc necessari notic odditi system 
the patent grant pursuant patent act cth act 
the ground revoc set act 
the act enact repeal act contain transit save provis Ch 
section follow patent grant act subject chapter regul act appli relat standard patent petti patent grant act patent grant act 
A patent mention subsect effect place effect immedi commenc day 
chapter act appli relat patent mention subsect 
object taken patent mention subsect patent invalid far invent claim claim ground would avail patent act 
the valid patent dealt Pt Ch act 
the revoc patent relevantli dealt act ground set 
those ground similar import differ provid act 
section act appli basi act patent revok ground provid act correspond similar ground avail act eg NV philip gloeilampenfabrieken v mirabella intern pti ltd fca fcr per lockhart J agre northrop J burchett J ici chemic polym ltd v lubrizol corp inc fca fcr abbott laboratori v corbridg group pti ltd fcafc ipr 
thi somewhat strang result ground correspond particularli relat lack novelti obvious 
uninstruct author I thought intent maintain statu quo relat revoc act patent time run act word ground revoc would set act 
that would maintain statu quo neither advantag disadvantag act patente 
howev approach reflect author contend either parti 
lack novelti section f g act follow A standard patent may revok either wholli far relat claim complet specif petti patent may revok one follow ground ground 
f invent far claim claim complet specif claim petti patent specif case may subject valid claim earlier prioriti date contain complet specif standard patent petti patent specif petti patent g invent far claim claim complet specif claim petti patent specif case may novel australia prioriti date claim prior claim ground avail case receiv wisdom applic act 
the applic reli upon follow public prior prioriti date claim suit australian patent No 
laid open public inspect australian patent offic januari patent translat french patent applic No 
grant without amend french patent No 
french patent b french patent applic No 
laid open public inspect australian patent offic march european patent applic No 
c canadian patent No 
laid open public inspect australian patent offic novemb canadian patent unit state patent No 
laid open public inspect australian patent offic septemb US patent 
origin emphasi 
each version french patent slightli differ languag 
relev portion french patent set 
particular refer made applic follow claim canadian patent detail french patent 
A process prepar deriv gener formula I Y may repres either hydroxyl radic group radic R straight branch lower alkyl radic Y repres radic formula either ident differ repres hydrogen atom straight branch lower alkyl group form togeth nitrogen atom attach heterocycl may may includ second heteroatom chosen group contain oxygen nitrogen wherein latter may substitut lower alkyl benzyl radic may may substitut X repres hydrogen halogen atom lower alkyl radic addit salt pharmaceut accept miner organ acid Y repres radic formula formula R mean miner base Y repres hydroxyl radic well enantiom mixtur compound formula I wherein either order prepar ester formula I Y repres radic formula R mean X mean pyridin formula II condens formula iii R X mean deriv sought obtain isol desir enantiom separ salifi miner organ acid action order prepar acid formula I Y repres hydroxyl radic X mean ester formula I Y repres radic formula R X mean saponifi deriv sought obtain isol desir enantiom separ salifi miner organ acid action order prepar compound formula I X mean Y repres radic formula R mean radic formula mean acid formula I X mean Y repres hydroxyl radic may may activ react either alcohol formula R mean amin formula mean correspond deriv sought obtain isol desir enantiom separ salifi miner organ acid action 
process accord claim prepar methyl 
chlorophenylacet wherein thieno pyridin condens methyl 
chlorophenylacet deriv sought isol obtain 
deriv gener formula I Y may repres either hydroxyl radic group radic R straight branch lower alkyl radic Y repres radic formula ident differ repres hydrogen atom straight branch lower alkyl group form togeth nitrogen atom attach heterocycl may may includ second heteroatom chosen group contain oxygen nitrogen wherein latter may substitut lower alkyl benzyl radic may may substitut X repres hydrogen halogen atom lower alkyl radic addit salt pharmaceut accept miner organ acid Y repres radic formula forrnula R mean miner base Y repres hydroxyl radic well enantiom mixtur compound formula I time obtain process claim manifest chemic equival 
methyl 
time obtain process claim manifest chemic equival 
emphasi ad 
the phrase g act novel australia similar substanc phrase act novel light variou kind inform 
To say claim patent novel sens say add noth new compar 
In case paper anticip assum product describ made process outlin follow 
each integ claim invent must disclos prior public 
the revers infring test practic way detect whether case meyer taylor pti ltd v vicarr industri ltd hca clr 
the patent suit claim chemic compound specif properti name capac rotat light right 
that properti distinguish racem enantiom 
the enantiom expressli identifi french patent 
counsel submit possibl face earlier specif say enantiom said racem 
furthermor said differ signific far pharmacolog efficaci toxic concern disclos complet specif patent suit 
thu patente content someth new differ novel form substanc 
On hand formula identifi deriv exampl french patent correspond patent pcr ident formula enantiom suit 
I satisfi skill invent reader french correspond patent would understand deriv question common deriv racem technic explan mean obtain deriv test relat racem individu enantiom 
there express suggest either enantiom fact separ obtain test efficaci toxic 
that said commonli known spell french patent compound question racem one chiral centr two enantiom one dextro levo 
there express refer enantiom bodi specif claim french correspond patent detail clearli spell canadian patent 
the express refer enantiom french correspond patent particularli canadian patent plainli carri claim enantiom within compound disclos 
the relev phrase french canadian patent specif the invent relat enantiom mixtur french patent the invent also concern enantiom mixtur canadian patent claim well two enantiom mixtur 
french canadian patent desir enantiom separ salifi canadian patent claim well one two enantiom mixtur french patent well enantiom mixtur canadian patent consist disclosur claim enantiom dextro levo separ racem 
I say attempt wit patente deni claim patent encompass separ singl enantiom say least impress 
the basi french correspond patent compound class claim whether exemplifi display use inhibit action platelet aggreg activ 
the precis effect differ variou exampl discuss 
although compound test racem distinct pharmacolog properti drawn racem singl enantiom 
It follow patente assert relev qualiti enantiom relevantli distinguish particular racem enantiom 
the claim separ enantiom could describ bare claim efficaci without foundat shown part complet specif 
there basi know efficaci toxic would appli either enantiom particular racem 
It known cours one enantiom pcr almost complet ineffect significantli toxic 
that may exorbit covet claim cf mullard radio valv Co ltd v philco radio televis corpor great britain ltd all ER rpc 
No doubt racem claim would larg risk would protect competit drug one enantiom activ ingredi might efficaci perhap efficaci racem activ ingredi 
the covet natur claim advanc posit 
the enantiom pcr identifi compound use qualiti concern platelet aggreg 
the truth falsiti claim advantag relev purpos 
counsel submit enabl disclosur mere disclosur requir anticip cite recent lindgren J alphapharm pti ltd fca decis hous lord smithklin beecham paroxetin methanesulfon patent rpc 
By way introduct worth remark phrase enabl disclosur brought promin speech lord hoffmann biogen inc v medeva plc ukhl rpc ipr 
that decis concern requir valid patent unit kingdom act base upon european patent convent concern question anticip 
the import question whether later patent could claim earlier prioriti date support earlier specif 
that concept similar narrow whether later patent fairli base upon earlier specif law cf F roch Co AG v commission patent hca clr ccom pti ltd v jiej pti ltd fca fcr lockwood secur product pti ltd v doric product pti ltd hca clr 
It may accept case claim chemic compound formula order valid specif would disclos might manufactur 
the phrase also use speech lord oliv asahi kasei kogyo KK applic rpc I shall return 
the phrase reason shorthand relat disclosur requir anticip process method claim opinion littl relev anticip product claim claim chemic compound formula 
inde apt mislead relat latter 
for product claim novelti must lie product mean produc may baker ltd v boot pure drug Co ltd rpc 
By token new process obtain old product novelti 
the usual start point discuss anticip judgment lord westburi LC hill v evan ipr De GF J LJ Ch LT ER particularli follow ipr anteced statement must person ordinari knowledg subject would perceiv understand abl practic appli discoveri without necess make experi gain inform invent made use 
If someth remain ascertain necessari use applic discoveri afford suffici room anoth valid patent 
there I think gener answer given question inform alleg invent given prior public must purpos practic util equal given subsequ patent 
the invent must shewn made known 
whatev therefor essenti invent must read prior public 
If specif detail necessari practic work real util alleg invent must found substanti prior public 
none report set particular plaintiff patent 
for detail necessari go relat case hill v london gaslight Co H N refer lord westburi LC hill v evan ipr 
the descript invent improv mode compress peat manufactur ga obtain certain substanc applic purifi 
It consist pass ga mixtur object purifi ga renov purifi materi 
each specif cite hill patent also process method patent 
heard patent applic lime purif ga croll patent direct improv method purifi coal ga ammonia lame patent also dealt process purif ga 
the gener statement lord westburi LC need understood context fact case 
with qualif mention principl establish integ invent must prior specif novelti defeat 
In case process method mean integ process method 
the qualif express variou place includ lord reid C van der leli NV v bamford ltd rpc but lord westburi must meant experi view discov someth disclos 
He meant refer ordinari method trial error involv invent step gener necessari appli discoveri produc practic result 
In case question whether skill reader would infer photograph machin magazin articl rake wheel alleg anticip machin ground driven rather gear driven 
It interest lord reid went say rpc the appel first argument enough photograph disclos probabl wheel ground driven 
there anticip say unless shown clearli unmistak 
I accept argument 
I would agre anticip materi must good practic purpos materi appel specif 
but I see practic differ definit statement fact materi skill man would clearli infer exist 
So question whether typic skill man would infer ground drive photograph 
It would enough man would guess 
but case I think prove ordinari skill man would good ground reach conclus wheel ground driven 
He could certain practic men act someth less absolut certainti 
the refer lord reid clearli unmistak doubt refer sourc lay behind passag later court appeal judgment gener tire rubber Co v fireston tyre rubber Co ltd rpc If prior inventor public contain clear descript clear instruct make someth would infring patente claim carri grant patente patent patente claim shown lack necessari novelti say anticip 
the prior inventor howev patente may approach devic differ start point may reason may reason describ devic immedi discern read languag respect use discov truth devic carri direct contain prior inventor public inevit result someth made done patente patent valid would constitut infring patente claim circumst demonstr patente claim fact anticip 
If hand prior public contain direct capabl carri manner would infring patente claim would least like carri way would patente claim anticip although may fail ground obvious 
To anticip patente claim prior public must contain clear unmistak direct patente claim invent flour oxid Co 
ltd 
v 
carr Co 
ltd 
R 
P 
C 
line approv B 
T 
H 
Co ltd v metropolitan vicker electr Co 
ltd 
R 
P 
C 
line 
A signpost howev clear upon road patente invent suffic 
the prior inventor must clearli shown plant flag precis destin patente 
emphasi ad 
the sourc flour oxid Co ltd v carr Co ltd rpc concern invent mprovement condit improv qualiti recent ground flour semolina like one claim relev patent process condit flour like pass full exposur atmospher contain gaseou oxid nitrogen chlorin bromin oxidis agent gaseou vapouris state 
the alleg anticip discuss parker J relev passag flour oxid Co ltd rpc entitl mprovement relat treatment alimentari substanc beverag essenti subject substanc action electr 
the patent suit gener tire rubber Co rpc process make compound suitabl tyre tread mix synthet rubber oil carbon black compound thu made 
the issu gener tire rubber Co rpc appear gener treatment anticip focuss upon method process 
the refer signpost flag excit later imagin deal situat languag direct given process method equivoc 
the main principl prior inventor public contain clear descript someth would infring patente claim carri grant patente patent patente claim shown lack necessari novelti 
altern prior inventor public contain clear instruct make someth would infring patente claim carri grant patente patent patente claim shown lack necessari novelti 
the first case I refer suggest disclosur chemic compound formula disclosur purpos anticip decis falcon J Re genentech inc human growth hormon patent rpc held disclosur chemic compound prior document anticip later claim compound cite document must contain suffici direct enabl compound made rpc 
asahi kasei kogyo KK applic rpc concern unit kingdom act 
counsel comptrol patent neatli opinion correctli sum law previous stood follow way rpc novelti fundament patent law 
prior act settl law U 
K 
prior inventor public contain clear descript clear instruct make someth would infring patente claim carri grant patente patent patente claim shown lack necessari novelti see gener tire v 
fireston R 
P 
C 
p 
accordingli act claim chemic compound held anticip statement prepar gyogyszeripari R 
P 
C 
method prepar work skf R 
P 
C 
the latter case consist gener tire instanc prior document contain descript invent 
the hous lord upheld contrari view falcon J Re genentech inc human growth hormon patent rpc 
the act includ word made avail public 
counsel asahi rpc suggest may made differ test 
falcon J reason appear depend upon distinct although refer decis technic board appeal european patent offic support posit 
falcon J expressli declin follow decis patent appeal tribun gyogyszeripara kurato interzet applic rpc smith kline french laboratori applic rpc establish practic comptrol 
counsel petition revoc case submit departur long stand law unit kingdom anticip I agre submiss 
lord hoffman speech smithklin beecham paroxetin methanesulfon patent rpc spell current unit kingdom posit clariti 
under unit kingdom act disclosur enabl separ concept cumul requir anticip although may circumst disclosur also satisfi enabl 
In opinion least relat product claim claim chemic compound formula departur law australia english law appli 
I would respect suggest creat anomal relationship anticip infring 
In present case earlier patent gave monopoli relat make use pcr enantiom togeth separ even though descript method resolv enantiom 
I ventur view claim symmetri disclosur requir valid earlier patent disclosur anticip purpos exist anomal case chemic compound describ adequ formula 
nonetheless lord hoffman speech use respect 
So far immedi point concern deal disclosur said smithklin beecham paroxetin methanesulfon patent rpc did synthon applic disclos invent perform would infring SB patent becaus cover class chemic defin refer formula disclos myriad compound may regard invent 
but matter one invent crystallin pm claim patent 
there seem doubt applic disclos exist pm crystal per cent puriti claim could made 
whether fact could made question enabl I shall come moment 
but exist advantag pharmaceut use clearli disclos applic 
and basi judg find monomorph pm crystal per cent puriti must necessarili characterist crystal claim patent includ IR xrd spectra 
At said It follow whether would appar anyon time whenev describ prior disclosur capabl perform perform must result patent infring disclosur condit satisfi 
the flag plant even though author maker prior art awar 
then In case disclosur matter reli upon prior art consist case written descript skill person taken tri understand author descript meant 
hi common gener knowledg form background exercis construct kind recent discuss hous inc v hoechst marion roussel ltd ukhl R 
P 
C 
and cours patent must constru similar principl 
but mean prior disclosur patent determin disclosur either invent perform would infring patent 
the person skill art part play 
the applic contend event method resolv enantiom part common knowledg skill person australia prioriti date would appli matter routin 
It submit behalf neither pcr either enantiom compound taught sens recommend french patent cite squibb Co v FH fauld Co ltd fca fcr per black CJ lehan J 
that case concern method administr natur occur drug patient 
the full passag follow what author contempl view prior public destroy novelti must give direct make recommend suggest result skill reader follow claim invent 
A direct recommend suggest may often cours implicit describ commonli question may whether public describ suffici clariti claim invent case combin integ 
that languag quit convent relat dose regim 
the actual decis case anticip dosag regim claim patent suit earlier public includ follow squibb Co fca fcr further studi evalu feasibl shorter infus time hour versu hour lower versu maximum toler dose progress relaps ovarian cancer patient canada europ 
alreadi patient enter random ncic guid intern studi 
inde hour infus time administr schedul prove feasibl given concomitantli profylact sic measur high dose dexamethason cimetidin difenhydramin 
thi make even outpati treatment first avail repres new class antitumor agent possibl 
cf merck Co inc v arrow pharmaceut ltd fcafc fcr 
In event problem aris present case 
the invent disclos claim french patent necessarili carri implic direct recommend suggest 
that consider monopoli grant 
someth sought made fact pcr deriv unmistak point best compound 
there compet evid expert relat question 
In view red her far novelti concern 
On view expressli disclos one promis compound 
the invent limit effect promis exampl 
the invent broad class 
As lord hoffmann lucidli explain biogen inc ukhl rpc ipr If invent disclos principl capabl gener applic claim may correspondingli gener term 
the patente need show prove applic everi individu instanc 
On hand claim includ number discret method product patente must enabl invent perform respect 
thu patente hit upon new product benefici effect demonstr common principl effect share product class entitl patent product class even though may subsequ turn benefici effect see may baker ltd v boot pure drug Co ltd rpc 
On hand disclos benefici properti common class entitl patent product class assum new even though made one two 
In word exampl use show util invent whole provid basi generalis balanc class claim 
the invent french correspond patent describ refer particular result efficaci toxic claim limit 
In opinion clear formula pcr expressli disclos claim advantag claim made relat enantiom 
the said specif exampl 
the patent suit identifi enantiom exampl activ enantiom none efficaci least good racem less toxic racem 
howev enantiom pcr clearli enough within compound claim french correspond patent benefici effect illustr result test pcr exampl 
that disclosur anticip claim patent suit unless view select patent somewhat controversi topic 
befor consid I digress author concern racem includ two recent case I refer earlier 
lindgren J dealt somewhat similar situat alphapharm fca although case express refer claim enantiom racem alleg anticip 
hi honour constru relev claim patent suit relat enantiom citalopram separ exist indistinguish part unresolv racem 
hi reason includ follow alphapharm fca the context I take account arriv conclus part common gener knowledg racem contain equal part enantiom enantiom racem potenti separ possibl enantiom might stabl exist compound distinct part racem racem fact resolv separ enantiom racem commonli repres symbol indic presenc enantiom 
It compound exist part racem 
the skill addresse would understand exist whether part racem apart purpos symbol distinguish mere part racem mixtur 
the symbol devoid context suggest otherwis impli distinct racem 
In alphapharm fca professor martin banwel call applic revoc case 
after refer passag gener tire rubber Co rpc cite variou case honour said alphapharm fca what enabl disclosur mean context product claim It mean earlier disclosur must point unmistak citalopram distinct racem drug desir obtain 
I take distinct mean separ instead oppos 
thi includ separ requir enabl accord smithklin beecham paroxetin methanesulfon patent rpc consist opinion 
It alleg product claim patent suit case anticip australian citalopram patent 
hi honour reject argument follow basi alphapharm pti ltd fca the australian citalopram patent refer enantiom 
It expressli implic otherwis disclos individu enantiom 
It disclos racem enabl obtain 
whether anticip present invent turn construct patent see section C 
the skill addresse read australian citalopram patent would understood consist citalopram would abl identifi formula S R enantiom would known absenc experiment 
these fact would howev point specif independ exist enantiom accord construct patent specif essenc claim 
If I constru claim refer present unresolv racem australian citalopram patent would anticip 
but construct outlin section C person taught australian citalopram patent although taught desir obtain racem would taught desir obtain specif right 
similarli australian citalopram patent citalopram formula disclos independ exist 
I note In adamson author proposit patent racem necessarili anticip claim invent either enantiom I respect disagre 
A littl earlier decis alphapharm fca young J consid similar issu ranbaxi australia pti ltd v Co llc No fca ipr 
one question whether formula claim relev patent claim racem enantiom separ racem 
the patente call amongst wit professor christoph easton professor peter scammel gave evid case 
the applic revoc ranbaxi call inter alia Dr keith watson call apotex one applic case 
hi honour find common gener knowledg far relev follow ranbaxi fca ipr the biolog activ racem biolog system quit differ singl enantiom 
the physic biolog properti racem differ individu enantiom variou respect exampl may differ solubl racem enantiom differ pharmacolog properti 
the normal expect would one enantiom approxim twice activ racem term oper target biolog system 
befor may skill team would expect R enantiom like activ activ enantiom could known certainti without isol test enantiom 
convers like case S enantiom inact substanti less activ R enantiom could known certainti enantiom isol test 
well may common gener knowledg amongst medicin chemist racem mixtur could separ individu enantiom method resolut 
inde undergradu chemic student taught procedur resolv enantiom 
It also gener known may enantiom could obtain chiral synthesi 
As may feasibl use resolut chiral synthesi obtain singl enantiom drug 
pharmaceut compani produc singl enantiom synthet drug either way resolut correspond racem mixtur way chiral synthesi prior may 
As may known enantiom could differ biolog properti may desir separ remov less activ enantiom 
hi honour found formula includ claim enantiom notwithstand refer 
An import part reason follow ranbaxi fca ipr perhap import background consider claim patent must constru skill addresse would know reductas inhibitor class compound refer claim enantiomer one enantiom like activ 
the skill addresse would also know biolog activ racem differ singl enantiom activ activ enantiom approxim twice activ racem 
In circumst confront structur formula claim show rel stereochemistri skill reader would consid structur formula intend claim enantiom well racem mixtur 
I think skill addresse would read structur formula one intend exclud activ enantiom 
read specif whole skill addresse would discern patente isol individu enantiom absolut stereochemistri activ enantiom less activ enantiom defin 
the skill addresse would also know yet done patente routin step obtain individu enantiom resolv racem mixtur also possibl make individu enantiom chiral synthesi 
In circumst skill addresse would expect absenc clear indic contrari claim patent intend includ activ enantiom 
In circumst absenc clear indic languag contrari skill addresse may would read claim encompass individu enantiom well mixtur 
As submit would make sens exclud patent protect activ enantiom 
the point well made professor easton cours affidavit evid said confin subject patent racem mixtur would exclud thing activ activ enantiom person work field may would know key use activ compound disclos patent 
It disput structur formula I would constru skill addresse includ tran racem compound formula 
but reason skill reader would constru formula mean tran racem therebi exclud enantiom 
In absenc clear indic contrari offend common sens constru structur formula I way 
young J refer decis patent england unit state adopt similar construct 
the full court upheld decis young J basi conclus open judg evid although full court appear adopt judg reason ranbaxi fcafc 
although decis alphapharm fca ranbaxi fca ipr turn larg measur upon evid case differ approach detect question involv disclosur enantiom ranbaxi fca ipr favour applic issu alphapharm fca neutral 
In neither case express refer enantiom french correspond patent 
the prioriti date relev patent also interest compar prioriti date issu 
In ranbaxi fca ipr prioriti date broader patent may enantiom patent juli 
In case alphapharm fca australian citalopram patent prioriti date januari enantiom patent june 
the common gener knowledg found lindgren J relat enantiom patent young J relat broader patent much time band relev construct patent suit 
natur field invent somewhat differ principl stereochemistri understood time vari much 
there suggest crucial wide known develop year question 
In encyclopedia unit kingdom european patent law sweet maxwel limit footnot page includ follow It instanc held public exist optic activ compound public separ optic activ form even though chemist would appreci must exist could prepar I 
C 
I 
unrep 
No 
oppos sandoz P 
A 
T 
the case could treat select patent 
but cf 
ant SS 
A similar view taken epo E 
P 
O 
R 
enantiom E 
P 
O 
R 
E 
P 
O 
R 
the case seem distinguish degre earlier public specifi enantiom form part disclos invent 
later author said page the teach racem amount teach singl enantiom least absenc clear identif relev chiral site indic enantiom encompass disclosur 
european patent offic decis applic correspond patent suit 
I return select patent 
there littl discuss topic australian author I refer australian judici decis base upon 
counsel applic submit refer act act warrant recogn special class patent australia 
the commentari lahor patent trade mark relat right lexisnexi butterworth australia describ lukewarm 
even unit kingdom topic dealt number author firmli entrench comment remain somewhat sceptic principl 
the situat affect unit kingdom act base upon european patent convent 
encyclopedia unit kingdom european patent law thorley S miller R burkil G birss C campbel D terrel law patent th edn sweet maxwel london 
the recent refer topic australia full court ranbaxi fcafc A patent applic overcom prior public select patent follow criteria met must substanti advantag secur use select member whole select member must possess advantag question select must respect qualiti special charact fairli said peculiar group advantag possess select member must clearli disclos specif 
see Re IG farbenindustri AG patent rpc 
howev said consid ground fals suggest rather lack novelti 
It fair brief summari posit understood time act base upon author refer made Re IG farbenindustri AG patent rpc 
thi remain basi law unit kingdom least decis hous lord EI Du pont De nemour Co witsiep applic fsr 
the first case unit kingdom court appeal consid select patent In matter esso research engin Co applic shell rpc principl explain follow rpc So may first scientist discov disclos whole rang may obtain patent protect discoveri mean manufactur maugham J 
call origin patent 
but within rang room also second scientist whose research may discov disclos certain item section advantag peculiar hitherto unknown would appear ground reason principl patent protect proper case avail second scientist 
see also institut francai du petrol de carbur et lubric applic Re fsr rpc may baker ltd rpc 
crennan J made pass refer patent addit I shall return select patent imperi chemic industri pti ltd v commission patent fca alr ipr aipc 
her honour also refer decis deleg barker univers georgia research foundat inc v biochem pharma inc ipr aipc 
It quit clear decis commission patent appli IG farbenindustri AG patent rpc principl mani year see also pfizer inc v commission patent fca fcr 
gummow J made delphic refer topic nicaro hold pti ltd v martin engin Co alr ipr aipc refer decis falcon J Re genentech inc human growth hormon patent rpc said elect patent may requir special attent matter anoth day 
As I said earlier decis falcon J appear opinion departur manner law anticip understood unit kingdom australia time 
It seem late day find principl explain maugham J IG farbenindustri AG patent rpc relev question anticip act act matter 
that recognis special class patent refer select patent conveni shorthand pick relev principl concern anticip 
I approach unit kingdom case includ EI Du pont De nemour Co witsiep applic fsr caution 
I must also endeavour keep separ question anticip one hand obvious 
the distinct alway easi discern author topic includ semin judgment maugham J 
there question whether select patent principl appli compound specif identifi earli specif member larger class eg exampl deriv whether restrict express identif first time particular member larger class special characterist 
the latter conced patente EI Du pont De nemour Co witsiep applic fsr 
In court appeal buckley LJ favour view concess necessari hous lord lord simon prefer leav point open fsr 
I favour view buckley LJ accord rational explain maugham J descript class follow IG farbenindustri AG patent rpc the second class compris patent select patent base select relat compound homologu substitut deriv origin compound presum describ gener term claim origin patent 
If view correct patent suit select patent ordinari sens pcr enantiom expressli disclos claim earlier patent expressli refer patent suit 
In one sens enantiom select 
there author suggest select small class per buckley LJ beecham group ltd amoxycillin applic Re rpc EI Du pont De nemour Co witsiep applic fsr per lord wilberforc cf institut francai du petrol de carbur et lubric applic Re fsr rpc 
I therefor assum contrari opinion principl appli present case basi requir met 
It conveni state summari requir full court decis ranbaxi fcafc must substanti advantag secur use select member whole select member must possess advantag question select must respect qualiti special charact fairli said peculiar group advantag possess select member must clearli disclos specif 
there substanti advantag secur use enantiom pcr compar use either racem mixtur enantiom 
It better toler less toxic either effect racem lesser concentr 
that prove differ success pharmaceut drug otherwis 
In sens first criteria satisfi 
the second fourth criteria also obvious satisfi 
howev select respect qualiti special charact It recal complet specif french patent correspond patent describ advantag invent follow the toxicolog pharmacolog investig report demonstr low toxic compound invent well excel toler inhibit properti aggreg activ make use medic therapeut applic 
the claim limit particular result 
In opinion good descript perform enantiom pcr 
It obviou specif french correspond patent claim compound within class would equal qualiti inde report test demonstr advantag describ gener 
the third proposit explain maugham J IG farbenindustri AG patent rpc follow If five thousand possibl member group hundr select possess new definit advantag intend assert select patent would bad shown result research exist anoth hundr member possess advantag 
If hand establish thousand unselect member possess advantag I doubt much whether patent could sustain 
the qualiti must special charact 
It must one skill art expect find larg number member 
It would rash attempt closer definit question ultim one appreci 
return old fashion metaphor I would say citadel must defend reward gate open first blast trumpet 
I summaris conclus I arriv say select patent invent step lie select use special properti characterist adequ defin proposit kept mind consid applic amend petit revoc 
the phrase In matter esso research engin Co applic shell rpc advantag peculiar lord wilberforc put EI Du pont De nemour Co witsiep applic fsr unrecognis advantag 
buckley LJ said beecham group ltd amoxycillin applic Re rpc 
substanc must truli new advantag gain select must inventor discoveri oppos mere verif previou predict previous predict word must unexpect 
the specif question doubt drawn concept mind 
howev advantag differ kind describ predict earlier patent specif 
even advantag could satisfi quantum leap relat earlier claim advantag result mean rang result predict test done exampl earlier specif 
there debat expert whether unexpect differ enantiom perform would great ascertain test 
In view present purpos fals issu 
the question whether advantag characterist enantiom unexpect 
for reason question three possibl racem enantiom best either compar member wider class 
I therefor conclud claim defend valid select anticip cite specif 
thi conclus also affect claim 
claim requir consider 
there disclosur precis formula claim cite specif claim either 
the closest specif prior art patent come refer addit salt pharmaceut accept miner organ acid 
It contend choic acid make salt compound routin 
the specif natur refer salt racem rather enantiom 
In event choic acid made said necessari disclosur anticip particular claim 
there clear descript salt describ claim clear instruct make particular salt earlier specif 
the attack novelti claim fail 
claim need consid 
none cite prior art specif contain descript process accord claim 
claim process separ enantiom plu salt format 
the earlier specif question rise statement claim canadian patent desir enantiom separ 
the evid one method resolv separ enantiom racem compound kind known prioriti date 
therefor choic involv reason appli appli relat claim 
the challeng novelti relat claim fail 
anticip deadli requir accuraci sniper fire gaug shotgun 
lack invent step section e act follow A standard patent may revok either wholli far relat claim complet specif petti patent may revok one follow ground ground 
e invent far claim claim complet specif claim petti patent specif case may obviou involv invent step regard known use australia prioriti date claim 
section act follow for purpos act invent taken involv invent step compar prior art base unless invent would obviou person skill relev art light common gener knowledg exist patent area prioriti date relev claim whether knowledg consid separ togeth inform mention subsect 
the inform purpos subsect singl piec prior art inform b combin piec prior art inform inform skill person mention subsect could prioriti date relev claim reason expect ascertain understood regard relev case inform mention paragraph b combin mention paragraph 
ground amend particular invalid follow lack invent step 
the patent invalid liabl revok insofar relat claim specif ground alleg invent patent invent within mean b act alleg invent involv invent step 
particular 
the alleg invent would obviou light common gener knowledg australia prioriti date claim common gener knowledg 
the applic submit attempt prove compound formula I refer p line patent form part common gener knowledg otherwis relianc 
line patent b person skill relev art australia would abl arriv compound formula I basi otherwis common gener knowledg 
further altern applic reli admiss made page line patent 
further altern extent alleg invent resid select invent disclos french patent enantiom mixtur enantiom disclos french patent alleg invent possess substanti advantag invent disclos french patent enantiom mixtur enantiom disclos french patent b altern alleg invent possess substanti advantag kind refer would unexpect light common gener knowledg australia prioriti date claim c altern substanti advantag kind refer b shown face specif 
such particular may provid time time 
origin emphasi 
I consid claim basi contrari opinion anticip 
A threshold question law aris 
It submit patente accept clopidogrel part common gener knowledg australia let alon broader teach french patent ground lack invent step misconceiv possibl success 
It point statutori phrase known use australia prioriti date 
It phrase refer common gener knowledg relev field australia say background knowledg experi avail trade consid make new product make improv old minnesota mine manufactur Co v beiersdorf aust ltd hca clr 
the applic seek sidestep consider obstacl reli upon descript invent step complet specif make clear step go racem mixtur correspond formula methyl thieno pyridyl acet describ deriv french patent enantiom racem mixtur 
the invent step would judg accord australian common gener knowledg 
It submit approach consist major high court aktiebolaget ssle v alphapharm pti ltd hca clr 
that consist way case conduct aktiebolaget ssle v alphapharm pti ltd fca ipr 
An invent step requir particular process invent flash geniu 
howev must step one thing anoth 
In case semin invent may littl someth 
the might said origin invent 
where inventor describ step refer start point base line end point result invent step judg exampl invent base line start point 
In make judgment standard test whether hypothet addresse face problem would taken matter routin whatev step might led prior art invent whether step inventor 
wellcom foundat ltd v VR laboratori aust pti ltd hca clr per aickin J 
aktiebolaget hca clr provid good exampl 
the compound known omeprazol undoubtedli involv invent step easili formul satisfactori pharmaceut composit solv problem administr drug formul requir gist invent step claim case 
obvious judg basi omeprazol discov simpli pass australian common gener knowledg 
By analog present case invent describ specif move particular racem compound enantiom compound 
It would obvious otherwis step would test obvious formul clopidogrel compound encompass french patent 
On basi state australian common gener knowledg would still import part play judg invent 
It easi imagin would technic field littl australian common gener knowledg exampl may routin laboratori switzerland would invent australian standard 
On hand may field relev australian knowledg advanc countri claim invent took place lead opposit conclus 
It difficult see patent could valid without disclos start point master patent specif 
To would amount obtain patent fals suggest represent within mean k act breach act describ invent see sami S svendsen inc v independ product canada ltd hca clr 
the appli act 
henc necess spell step advantag complet specif Re IG farbenindustri AG patent rpc institut francai du petrol de carbur et lubric applic Re fsr rpc 
the specif patent suit draft consist oblig 
the case select patent discuss novelti obvious refer natur select earlier patent specif later claim 
thi submiss describ heret 
I therefor care reread analysi e act aickin J minnesota mine hca clr particularli 
that analysi direct question aris 
there indic case patent specif reli upon cite patent suit connect patente patente awar 
It select patent sens 
the posit establish minnesota mine hca clr rel short durat 
until wider view william J hpm industri pti ltd v gerard industri ltd hca clr appli see graham hart pti ltd v SW hart Co pti ltd hca clr per aickin J 
the act widen prior art base chang natur issu 
leav asid aktiebolaget hca clr princip survey topic high court sinc minnesota mine hca clr lockwood secur product pti ltd v doric product pti ltd No hca alr aljr particularli 
that case involv problem aris 
It noteworthi court said provis As state enlarg prior art base includ relev prior disclosur beyond disclosur proven part common gener knowledg provis rais threshold invent 
howev idea remain prior disclosur taken account even enlarg consid particular purpos 
that purpos purpos look forward prior art base see person skill relev art like done face similar problem patente claim solv invent 
emphasi ad 
cf firebelt pti ltd v brambl australia ltd hca alr aljr combin patent 
the applic seek utilis content prior specif admiss common gener knowledg cf lockwood secur product hca alr aljr 
rather statement natur invent step claim cf anoth context commission patent v microcel ltd hca clr 
the submiss patente would consequ pursuant act person includ foreign patente could take foreign patent publish australia time ago wide known make suffici chang avoid anticip could seek patent without run gauntlet obvious even chang routin field australia time take care disclos exist foreign patent avoid charg fals suggest represent describ invent 
that patent would term commenc 
that result 
the patente argument easili reconcil exist Pt vii act deal patent addit improv modif main invent particularli follow object shall taken applic patent addit far invent claim claim complet specif patent addit far invent claim invalid ground invent far claim claim complet specif obviou involv invent step regard public main invent prioriti date claim prioriti date claim specif main invent defin invent improv modif subject claim two claim defin invent prioriti date whichev claim earlier earliest prioriti date b use main invent period 
A patent addit expir origin patent cf Ch act 
It observ section protect invalid ground obvious novelti regardless state common gener knowledg australia 
for interest exampl patent addit similar context see beecham group ltd amoxycillin applic Re rpc 
On hand start point baselin known field australia select compound may seen larg advanc invent step one leap may valuabl contribut relev field 
It may case provid use product public thu justifi patent protect 
the applic content reject hand particularli case select patent prior public patent specif publish issu australia 
If content wrong object valid claim fail 
I consid posit content accept basi start point analysi invent step racem compound pcr disclos french patent 
the start point invent identifi complet specif suit racem mixtur deriv describ french patent applic 
there claim invent select racem mixtur other disclos french patent 
the invent claim ascertain enantiom exhibit platelet aggreg inhibit activ enantiom inact less well toler two 
It thu express select patent limit respect 
the specif suit explain express term reason motiv separ test enantiom compar result racem mix 
It assum enantiom might separ 
the reason cours disclos 
there statement exampl problem concern toler toxic known affect racem mix led search better altern 
the invent step claim relat product claim enantiom unexpect natur result 
It cours investig unexpect result occur 
that suffici provid subject matter use call invent appropri circumst 
the refer french patent complet specif patent suit suffici permit refer french specif understand context disclosur particular racem 
the discuss gummow J agre jenkinson J nicaro hold pti ltd alr apposit although direct novelti case 
the applic submit would also appropri inform skill addresse result test formul pcr taken place novemb decis made attempt obtain enantiom pcr 
In particular report side effect particular convuls death anim 
I reconcil submiss narrow basi upon invent step consid 
It also question whether would consist limit use evid inventor know put cf wellcom foundat ltd hca clr per aickin J 
the patente chose omit matter specif 
the result might describ unexpect light french specif much characterist enantiom within expect broad rang rather characterist enantiom particular inact 
It common gener knowledg among skill worker field australia prioriti date one two enantiom might contain activ 
In opinion discoveri characterist case unexpect amount invent step 
therefor contrari opinion claim novel consid light complet specif obviou involv invent step 
It becom necessari consid claim I consid novel 
the specif suit refer find salt among miner organ acid salt enantiom crystal easili hygroscop suffici make use activ medicin princip particularli advantag 
three salt particular identifi hydrogen sulfat taurochol hydrobromid 
the hydrochlorid identifi use powder form 
these compound subject claim 
the convers pure enantiom salt suggest particular difficulti describ achiev standard manner mean standard method 
the specif suit claim invent step method obtain salt clopidogrel known claim rest properti salt 
again critic issu correct start point 
If common gener knowledg australia prioriti date ground invalid must fail clopidogrel part common gener knowledg 
On hand start point recount specif patent suit includ racem mix pcr disclos french patent enantiom least substanc content claim obviou 
In view invent step judg basi either pcr enantiom start point 
It may seem anomal major compound might obviou statement specif suit salt 
howev salt novel without special consider select patent 
To take specif suit account way judg obvious claim would base upon gener principl restrict select patent 
there much said view patente held advanc art identifi specif purpos judg whether invent step 
put anoth way content specif suit would taken account identifi invent step purpos judg obvious 
howev author cite directli establish principl 
even applic select patent doubt 
A similar issu aros recent full court decis insta imag pti ltd v KD kanopi australasia pti ltd fcafc connect mechan invent act 
To extent decis applic case tend applic content use made statement specif suit invent step although reason altogeth clear see insta imag pti ltd fcafc 
the applic content step far singl judg 
It follow claim repres invent step compar common gener knowledg australia time 
If invent step identifi singl enantiom clopidogrel start point I would held salt claim obviou 
It known pharmaceut accept salt use administr activ compound 
It known prepar salt use known miner organ acid 
the acid chosen hydrochlor acid sulfur acid hydrobrom acid taurochol acid convent 
they except taurochol acid acid utilis relat salt pcr french patent 
standard method prepar salt known 
claim princip process claim 
It describ gener way process liber enantiom racem compound pcr mean diastereomer salt format 
the desir obtain enantiom racem compound taken grant 
the claim relat choic relat mean 
novelti lie fact prior art disclos use process relat particular compound obtain particular enantiom 
that method field australia prioriti date classic mean obtain enantiom racem compound 
what specif suit disclos classic method work case 
the patente sought establish princip Mr badorc firstli method alway work relat particular compound secondli applic method case requir choic made light difficulti encount cours carri standard obviou 
A number method obtain enantiom racem compound known prioriti date also contend choic one obviou 
none content detract fact claim repres classic process appli known compound produc desir result 
the relev Mr badorc evid issu doubt least 
even admiss opinion particular applic method Mr badorc involv invent step 
Mr badorc evid step took way diastereomer salt format lead success experi march challeng variou respect princip appar discrep evid contemporan record 
hi explan far convinc 
even evid accept step took typic trial error necessarili involv use techniqu 
even invent step particular applic Mr badorc claim limit 
each addit integ claim field australia prioriti date avail part ordinari process trial error 
they reflect particular invent step identifi Mr badorc 
the fact process may alway work particular circumst avail altern establish invent choos use 
the choic one known process known process may invent circumst perhap receiv wisdom would point direct result unexpect 
there circumst 
for sake complet I say invent step involv claim ascertain pharmacolog characterist respect enantiom 
given racem given desir obtain enantiom process describ claim obviou claim invalid 
manner new manufactur It contend applic claim suit repres invent manner new manufactur act combin definit invent act togeth definit invent dictionari sch 
the illumin discuss encompass manner manufactur high court nation research develop corp v commission patent nrdc case hca clr extend mean phrase accord principl develop applic statut monopoli explain refer author point 
In opinion could suggest subject matter present claim outsid extend notion 
the claim compound process field use pharmacolog applic 
that decis deliv sever month decis anoth full court high court commission patent v microcel ltd hca clr 
In case held specif disclos patent invent headnot succinctli summaris gist decis follow It invent idea monopoli claim take substanc known use make variou articl make articl known properti make suitabl although fact use make articl 
In NV philip gloeilampenfabrieken v mirabella intern pti ltd hca clr high court quot approv follow passag nrdc case hca clr per dixon CJ kitto windey JJ commission may properli reject claim process within concept manufactur 
but case cite ie microcel show also even process within concept commission bound accept alleg applic new appar face specif properli constru alleg unfound 
the latter decis subsequ discuss high court advanc build system pti ltd v ramset fasten aust pti ltd hca clr particularli per brennan CJ gaudron mchugh gummow JJ lockwood secur product hca alr aljr 
It made clear extern evid reli upon 
the ground invalid examin detail full court merck Co inc fcafc fcr cf first instanc arrow pharmaceut ltd v merck Co inc alr ipr 
the true scope ground invalid difficult discern case present claim convent product albeit defin chemic formula process manufactur product compar say merck Co inc fcafc fcr dealt variat dosag regim 
It clear ground novelti obvious must consid rather prism ccom pti ltd fca fcr 
In opinion said patent suit claim invent new face specif without regard may describ extern evid 
inde specif drawn fashion design ensur claim new content specif accept 
I agre french specif incorpor refer whole purpos specif suit 
It incorpor suffici understand refer racem compound specif suit 
even wrong incorpor whole appear case prior document full court decis merck Co inc fcafc fcr would take matter decis I come novelti 
fals suggest represent the next ground consid patent obtain fals suggest represent act k act 
the first fals mislead represent alleg statement unexpect manner enantiom Id exhibit platelet aggreg inhibit activ enantiom Il inact 
emphasi ad 
It accept statement rel activ accur alleg unexpect 
thi link follow represent the pharmacolog studi present demonstr interest inhibitori properti toward platelet aggreg compound Id absenc activ isom Il 
emphasi ad 
those statement obvious design support claim novelti enantiom counter suggest mere anoth use known substanc particular support claim novelti base upon select 
the represent statement the racem mixtur correspond formula describ french patent applic publish No 
It suggest use express racem mixtur impliedli repres french patent describ disclos enantiom compound refer patent 
that represent would go question novelti claim depend claim 
furthermor would establish earlier specif disclos enantiom way would destroy novelti 
In arrow pharmaceut ltd alr ipr I consid similar argument base upon said offic articl 
I said alr ipr thi difficult ground establish statement attack purport conclus drawn publish articl 
the patent offic other interest abl read articl form independ judgment 
the point would appli 
As I found claim depend claim lack novelti ground add noth result 
the act contempl revoc claim claim act ground patent obtain fals suggest represent k 
nonetheless full court ici chemic polym ltd v lubrizol corp inc fca fcr held open word act contempl claim claim revoc 
It submit patente descript unexpect interest express opinion falsifi made mislead establish genuin held 
that distinct field misrepresent mislead conduct contrari trade practic act cth defam 
there good deal commend approach context 
there materi intern document would provid support case 
howev point behalf case plead present applic 
further appear way issu approach full court ranbaxi fcafc consid object 
the decis full court ici chemic fca fcr may support object approach held fals suggest represent may made good faith although fals statement case could possibl regard statement fact statement opinion see ici chemic fca fcr 
view object fashion question ask presum answer would notion person skill art australia 
On basi I would conclud statement fals 
At prioriti date known field australia one end spectrum enantiom would contribut equal activ racem 
At end spectrum one would activ none 
both result known possibl usual result would somewher two 
predict without test regard reliabl 
To say possibl result one end spectrum even unlik unexpect categoris fals 
the statement result interest even difficult falsifi 
even statement fals must ask whether suggest represent materi induc factor led grant ici chemic fca fcr cite prestig group aust pti ltd v dart industri inc fcr per lockhart J per gummow J northrop J agre 
In ranbaxi fcafc said the ground fals suggest misrepresent must involv mislead decept commission commission deleg person make grant 
To establish ground must find commission commission deleg way misl deceiv suggest represent question misl deceiv contribut caus decis grant patent 
the commission parti proceed took substant part proceed 
the commission may taken view ranbaxi prosecut alleg ground invalid suffici vigour commission involv 
ranbaxi adduc evid way alleg fals suggest misrepresent oper decis make process commission 
where alleg patent obtain fals suggest misrepresent relev although decis commission made complaint misl deceiv 
In absenc alleg fraud involv examin state mind patent applic suffici make ground fals suggest misrepresent prove simpli fals mislead statement made noth els 
that say even suggest represent shown fals mislead suffici reason draw infer suggest represent contribut decis grant patent 
In present case explicit evid effect assert effect relev compound surpris unexpect enantiom patent would grant 
while infer drawn absenc evid concern commission decis make process infer must reason cogent 
origin emphasi 
In case examin question patent claim enantiom racem previous publish 
the statement found fals made behalf patente order overcom examin object 
In circumst full court agre conclus primari judg necessari element causat present 
howev present case patent offic file show indic examin consciou potenti problem rais one patente 
that approach full court ranbaxi fcafc would requir neg answer question whether fals statement materi induc decis see also ici chemic fca fcr 
In event I would inclin think time applic consid patent offic would regard descript find unexpect interest field select patent like patent attorney puff rather seriou statement fact 
inutil the last ground invalid consid alleg invent use act h act b togeth definit patent invent provid sch cumul 
the particular press hear follow 
the alleg invent achiev capabl achiev result promis specif light common gener knowledg enantiom compound exhibit activ unexpect manner suggest page line specif b inhibitori properti enantiom compound refer page line specif interest 
that way put ground hardli rise higher fals represent case fail reason 
that reliev decid whether event object misconceiv 
My inclin think 
util sens depend upon whether follow teach complet specif result claim produc advanc build system hca clr 
the result claim may cover two aspect one physic produc result produc result use 
use sens mean commerci success 
put anoth way gummow J rehm pti ltd v webster secur system intern pti ltd alr approv follow statement gener principl If invent intend patente end attain use invent use invent 
here suggest process claim work sens suggest compound claim use inhibit platelet aggreg 
inde contend compound claim better respect racem 
I see claim properti unexpect surpris anyth concept 
the decis young J ranbaxi fca ipr must base upon view specif constru promis particular level result 
the correct decis point left open full court ranbaxi fcafc 
conclus claim invalid ground lack novelti 
claim present frame fall 
claim inclus invalid ground lack invent step 
all ground invalid dismiss 
the proceed stand limit period order made either agreement argument includ order cost 
the parti also consid whether necessari issu overlook reason 
I certifi preced one hundr number paragraph true copi reason judgment herein honour justic gyle 
associ 
